heteromeric

NS3861 是烟碱型乙酰胆碱受体的激动剂，对α3β4 nAChR 具有高亲和力。能够分别与α3β4 (Ki:0.62 nM)、α3β2 (Ki:25 nM)、α4β4 (Ki:7.8 nM)、α4β2 (Ki:55 nM) 结合。

RO3 是一种能透过大脑的P2X3和P2X2 3拮抗剂，口服有活性。它对人同型多聚体 P2X3和异型多聚体 P2X2 3受体的 pIC50分别为 5.9 和 7.0。

NS3861 fumarate 是烟碱型乙酰胆碱受体 (nAChRs) 的激动剂。NS3861 fumarate 是α3β4 nAChR 的部分激动剂。与α3β4、α3β2、α4β4、α4β2 的结合Ki 值分别为 0.62、25、7.8、55 nM。

ASIC blocker (IC50 values are 0.44, 2.1 μM and no effect at rat ASIC1a, ASIC3 and ASIC2a, respectively: IC50 value = 0.12 μM at human ASIC1a with no effect at ASIC2a or ASIC3). Inhibition was also observed at heteromeric ASIC channels (IC50 values are 0.79, 0.87 and 4.5 uM at rat ASIC1a+3, ASIC1a+2a and ASIC2a+3; IC5O values are 0.33 and 0.69 uM at human ASIC1a+2a and ASIC1a+3, with no effect at ASIC2a+3). Attenuates pathophysiological nociceptive behaviors in CFA-inflamed and CCI rats.

CAY10680 is a dopamine-sparing, benzothiazinone compound that selectively inhibits both MAO-B activity (IC50 = 34.9 nM in human) and adenosine A2A receptors (Ki = 39.5 nM in human). It demonstrates significantly less potent inhibitory values for other adenosine receptor subtypes (Kis > 1 μM) and MAO-A (IC50 ≥ 10 μM). At 1-20 μM, CAY10680 has been shown to abolish cAMP accumulation in CHO cells transfected with adenosine A2A receptors. In the central nervous system adenosine A2A receptor expression is localized to dopamine-innervated areas where heteromeric complexes are formed with dopamine D2 receptors. Because inhibition of adenosine A2A receptors has been shown to enhance D2 receptor function, the blockade of adenosine A2A receptors has emerged as a potential treatment for Parkinson's disease. An additional strategy in the treatment of Parkinson's disease has been to block the activity of monoamine oxidase B (MAO-B), the enzyme involved in dopamine catabolism.

VUAA1为昆虫气味辅助受体（Orco）激动剂，能够激活具Orco的异聚及同聚通道，进而干扰害虫的破坏性行为，适用于昆虫嗅觉方面的研究。

BTD 是一种选择性瞬时受体电位经典 5 (TRPC5) 激活剂，可激活由 TRPC5 及其最近的亲属 TRPC1 或 TRPC4 组成的异聚通道复合物，可用于研究神经系统疾病。